Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indinavir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.99 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.99 |
| ▸ | TACR2 | P21452 | 1/20 | 0.99 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.99 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.99 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.99 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indinavir Anhydrous SCHEMBL17787450 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL7752012 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL8033526 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL13575769 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL6766271 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL14287519 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL20399698 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL21683359 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL21578565 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL1176257 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11980613-B2 | Methods for reversing HIV latency using BAF complex modulating compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-05-14 | — | — | US | disclosed |
| US-11807852-B2 | Compositions and methods for reactivating latent immunodeficiency virus | THE J. DAVID GLADSTONE INSTITUTES (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-11590110-B2 | Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220364119-A1 | COMPOSITIONS AND METHODS FOR TREATING AN IMMUNODEFICIENCY VIRUS INFECTION WITH A THERAPEUTIC INTERFERING PARTICLE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-17 | — | — | US | disclosed |
| US-11458148-B2 | Method and compositions for the treatment of anemia through the inhibition of furin | BRIGHAM YOUNG UNIVERSITY (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2022-07-14 | — | — | US | disclosed |
| US-20220193209-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS AND/OR TREATING IMMUNODEFICIENCY VIRUS INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-23 | — | — | US | disclosed |
| EP-3982996-A1 | COMPOSITIONS AND METHODS FOR TREATING AN IMMUNODEFICIENCY VIRUS INFECTION WITH A THERAPEUTIC INTERFERING PARTICLE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220090085-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2022-03-24 | — | — | US | disclosed |
| US-7495011-B2 | Anti-coronavirus drug | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495011-B2 | Anti-coronavirus drug | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| WO-2008145733-A2 | NOVEL CHEMICAL COMPOUNDS, PRODUCTION THEREOF, AND USE THEREOF | UNIVERSITÄT LEIPZIG (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-7202092-B2 | Indinavir derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202092-B2 | Indinavir derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7199240-B2 | Reductive alkylation of saturated cyclic amines | MERCK & CO., INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199240-B2 | Reductive alkylation of saturated cyclic amines | MERCK & CO., INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7193065-B2 | Protease inhibitor conjugates and antibodies useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070009593-A1 | Methods of treating cancer | Indianan University Advanced Research | 2007-01-11 | — | — | US | disclosed |
| WO-2004010937-A2 | METHOD OF TREATING CANCER | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE AT INDIANA UNIVERSITY (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807852-B2 | Compositions and methods for reactivating latent immunodeficiency virus | NSUN2, IRF3, DNMT3B | CYP3A4 4068/4885ABCC3 3910/4885ABCB11 4407/4885 |
| US-20220090085-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | NSUN2, IRF3, DNMT3B | CYP3A4 4068/4885ABCC3 3910/4885ABCB11 4407/4885 |
| US-20070009593-A1 | Methods of treating cancer | CAPN2, CAPN9, CAPN1 | CYP3A4 2906/4885ABCC3 2498/4885ABCB11 3462/4885 |
| US-20220193209-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS AND/OR TREATING IMMUNODEFICIENCY VIRUS INFECTION | HAVCR2, CD4, MAVS | CYP3A4 3109/4885ABCC3 3470/4885ABCB11 3927/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | CYP3A4 3014/4885ABCC3 3796/4885ABCB11 2499/4885 |
| US-11980613-B2 | Methods for reversing HIV latency using BAF complex modulating compounds | CHD1L, SMARCC1, CHD1 | CYP3A4 4332/4885ABCC3 2158/4885ABCB11 2229/4885 |
| US-11590110-B2 | Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor | GSK3B, GSK3A, GSKIP | CYP3A4 2605/4885ABCC3 4418/4885ABCB11 4233/4885 |
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | PLAT, PLG, PLAUR | CYP3A4 2759/4885ABCC3 3712/4885ABCB11 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.